

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/49797765>

Dinoxin B, a Withanolide from *Datura innoxia* Leaves with Specific Cytotoxic Activities

ARTICLE in JOURNAL OF NATURAL PRODUCTS · FEBRUARY 2011

Impact Factor: 3.8 · DOI: 10.1021/np1004714 · Source: PubMed

CITATIONS

5

READS

242

10 AUTHORS, INCLUDING:



Francisco Omar Holguin

New Mexico State University

30 PUBLICATIONS 227 CITATIONS

SEE PROFILE



Mary O'Connell

New Mexico State University

73 PUBLICATIONS 1,085 CITATIONS

SEE PROFILE



Julian Simon

Fred Hutchinson Cancer Research Center

48 PUBLICATIONS 4,000 CITATIONS

SEE PROFILE

Published in final edited form as:

J Nat Prod. 2011 February 25; 74(2): 267–271. doi:10.1021/np1004714.

Dinoxin B, a Withanolide from *Datura inoxia* Leaves with Specific Cytotoxic Activities

Karl Vermillion^{†, #}, F. Omar Holguin^{†, #}, Mark A. Berhow^{†, *}, Richard D. Richins[‡], Thurman Redhouse[‡], Mary A. O'Connell[‡], Jeff Posakony[§], Sumit S. Mahajan[§], Sean M. Kelly[§], and Julian A. Simon^{§, ⊥}

[†]United States Department of Agriculture, Agricultural Research Service, National Center of Agricultural Utilization Research, Functional Foods Research, 1815 N. University Street, Peoria, Illinois 61604

[‡]Plant and Environmental Sciences, New Mexico State University, PO Box 30003, Las Cruces, New Mexico 88003-6041

[§]Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109

[⊥]Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109

Abstract

A new withanolide, dinoxin B (12,21-dihydroxy-1-oxowitha-2,5,24-trienolide-27-*O*- β -D-glucopyranoside **1**), was isolated from a methanol extract of *Datura inoxia* leaves, using bioassay-guided fractionation. The structure was determined by spectroscopic techniques, including ¹H, ¹³C NMR, and 2D NMR experiments as well as by HRMS. Extracts and the purified compound were tested for their antiproliferative activities toward a panel of human normal and cancer cell lines. Dinoxin B (**1**) and its aglycone (**2**) exhibited sub-micromolar IC₅₀ values against multiple human cancer cell lines. Among the most sensitive were several breast cancer cell lines. Dinoxin B (**1**) was found only in *D. inoxia*, and was not detected in *D. metel* nor *D. stramonium*. The accumulation of this compound was limited largely to leaf tissue, with little to none detected in extracts from the flowers, fruits, roots or stems of *D. inoxia*.

The genus *Datura* belongs to the family Solanaceae, commonly known as the nightshade family. This genus contains many species indigenous to the American Southwest including *Datura ferox*, *D. inoxia*, and *D. stramonium*. The genus originates from the Old World and has a worldwide geographical distribution.¹ Medicinally, *Datura* extracts have been used for their anesthetic, demulcent, expectorant, hypnotic, intoxicant, and sedative properties and are used traditionally to treat asthma, earache, headache, and tumors. The genus *Datura* has been an important commercial source of alkaloids, particularly for its content of tropane alkaloids such as hyoscyamine.²

*To whom correspondence should be addressed. Tel: +001-309-681-6347. Fax: +001-309-681-6685. mark.berhow@ars.usda.gov.

#These authors contributed equally to this work.


*Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture. USDA is an equal opportunity provider and employer.

Supporting Information Available: The ¹H, ¹³C, DEPT, NOESY, HMBC, HSQC NMR spectra and IR spectrum for Dinoxin B (**1**); and the ¹H, ¹³C, COSY, HMBC and TOCSY NMR spectra for the aglycone (**2**) are available free-of-charge via the internet at <http://pubs.acs.org>.

Withanolides constitute a large family of plant steroids and steroid glycosides typified by a fused tetracyclic cholestane core and a side-chain unsaturated δ -lactone.³ Within the genus *Datura*, withanolides have been isolated from several species, although Evans² suggests that not all species in this very large genus accumulate this class of secondary metabolite. To date, reports on this class have appeared for *D. fastuosa*,⁴ *D. ferox*,^{2,5} *D. innoxia*,^{6,7} *D. metel*,^{8,9} *D. quercifolia*,^{8,9} and *D. stramonium*.^{8,9} In all cases, the withanolides were obtained from aerial parts of the plant, usually the leaves but in one case the flowers.⁴ There have been relatively few in vitro bioassays using withanolides from *Datura* spp. Kagale et al. demonstrated that extracts from *D. metel* leaves inhibited the growth of plant pathogens in vitro,¹⁰ and the most abundant compound in this extract had a mass spectrum that matched the published report for the withanolide, datruilin.¹¹ Pan et al. isolated ten withanolides from *D. metel* flowers and demonstrated that four were cytotoxic at 10 μ M or lower against three human cancer cell lines.⁹ Withanolides, such as withaferin A, obtained from other plant species, have been shown to induce apoptosis in the MCF-7 and MDA-MB-231 breast cancer cell lines.¹² Likewise, tubocapsenolide A induced apoptosis in the MDA-MB-231 cell line at low micromolar concentrations.¹³

In this study, we report the isolation and structure elucidation of a new withanolide (**1**) from a methanol extract of *D. innoxia* Mill. (*D. wrightii* Regel) leaves. The extract was fractionated by bioassay-guided separation using cytotoxicity towards the MCF-7 human breast cancer cell line to guide biological activity.

Crude extracts were fractionated by a combination of chromatographic techniques from the methanol leaf extracts of *D. innoxia*. The fraction with the strongest cytotoxic activity against the MCF-7 cell line was then purified to homogeneity by preparative HPLC with multi-wavelength PDA detection and characterized by high-resolution LC-MS. Infusion MS analysis on a Q-TOF mass spectrometer gave a large positive ion m/z 655, which was determined to be $[M+Na]^+$, with major fragments m/z 471 $[M-\text{glucose}+H]^+$ and 453 $[M-\text{glucose-water}+H]^+$. When the sample was analyzed by LC-MS, an ion at m/z 633 $[M+H]^+$ was associated with the single UV absorbing peak. Using a calibrated infusion run on the Q-TOF mass spectrometer, the molecular formula of (**1**) was determined as $C_{34}H_{48}O_{11}$, with a formula weight of 632.74 (calcd for $C_{34}H_{48}O_{11}Na$, 655.3088).



The diagnostic mass and NMR spectra suggested a steroidal lactone glucoside (Table 1: the 1H , ^{13}C , DEPT, HSQC, HMBC, and NOESY NMR spectra are provided as supporting information; Figures S1–S11). The ^{13}C and HSQC spectra showed the presence of a ketone, a carboxyl moiety and six olefinic carbons, three of which are protonated. The HMBC and COSY spectra showed all the double-bonded carbons to be isolated from each other. There were three methyls found on unprotonated carbons.

Beginning with the ketone at position 1, it was possible to follow the connectivity of the ABCD rings with the HMBC and COSY spectra and assign the basic steroidal structure. The COSY and HMBC spectra both showed the C-17 to C-20 connection as the branch point for the rest of the molecule. The COSY spectrum then followed from H-20 to H-22 to H-23, after which the HMBC spectrum was used to assign the rest of the lactone ring. The HMBC spectrum also showed the connection between methylene C-27 and C-1' of the glucose anomeric carbon. There were strong NOESY cross peaks from H-1' to H-3' and H-1' to H-5', implying that H-1', H-3' and H-5' are on the same side of the glucose ring. This requires that the glucose have the β -O configuration. Strong NOESY cross peaks from H-12 to H-9,

H-11a, H-14, H-17 and weak or absent cross peaks from H-12 to H-8, H-11b, H-18 and H-19 were used to determine the stereochemistry for most of the molecule. H-9, H-12, H-14 and H-17 were shown to be on one side of the molecule, and H-8, H-11b, H-18 and H-19 on the other. Strong NOESY cross peaks from H-18 to H-8, H-11b and H-19 and lack of cross peaks from H-18 to H-9, H-11a, H-12 and H-14 (all shown right) agreed with the configuration suggested above. The cross peak from H-18 to H-20 did not imply any stereochemistry due to the free rotation around the C-17—C-20 bond, as a strong NOESY signal would be present for any configuration at C-13, C-17, or C-20. Related 12-hydroxy compounds showing both (*R*) and (*S*) stereochemistry are found in *Datura* species at C-12.¹⁴

The configuration at carbons 8, 9, 10, 12, 13, 14, and 17 are as shown in the structure. The stereochemistry at C-20 was difficult to establish from the NOESY spectrum due to the free rotation of the C-17 – C-20 and C-20 – C-22 bonds. However, it was determined as (*R*) on the basis of a bioenergetic argument because all reported withanolides unsubstituted at C-20 have the same configuration.⁹ The stereochemistry at C-22 was determined to be (*R*) as the literature indicates that an α -oriented H at C-22 gives rise to $J_{22, 23}$ values of between 0.5 – 7 and 9 – 13.8 Hz, whereas the β -oriented form exhibits values between 2.5 – 7 and 2 – 5 Hz. The observed coupling constants for the proton at C-22 in **1** ($J = 12.8, 3.8$ Hz), fell under the former limits.^{15,16} Withametelinol,⁶ withametelin, and other related compounds were also shown to have C-22 (*R*) stereochemistry based on a positive Cotton effect around 250 nm.¹⁷

Accordingly, **1** was assigned the structure 12,21-dihydroxy-1-oxowitha-2,5,24-trienolide-27-*O*- β -D-glucopyranoside. It can be alternatively named ergosta-2,5,24-trien-26-oic acid, 27-(β -D-glucopyranosyloxy)-12,21,22-trihydroxy-1-oxo, δ -lactone. Compound **1** can also be classified as a sitoindoside, which is a withanolide containing a glucose group at the C-27 position.¹⁸

The ¹H and ¹³C NMR spectra of compound **2** contained shifts corresponding to the aglycone of compound **1** (Table 1: the ¹H, ¹³C, HMBC, COSY, and TOCSY NMR spectrum are provided as supporting information; Figures S13–S17). The NMR spectrum was similar to that of **1**, without the presence of the glucose moiety, but also suggests that it is a compound that is in equilibrium with an inseparable isomer.

The abundance of withanolides in the various organs of *D. inoxia* was investigated by monitoring methanol extracts by LC-MS and for the presence of the indicator *m/z* 655 ion (Figure S18, Supporting Information). Extracts from leaves, stems, roots, and flowers were prepared using the ASE extraction protocol up through the methanol extraction. At least four other withanolides were detected, but the most abundant form was the second peak, hence the name dinoxin B for compound **1**. The most abundant source of **1** was the leaves; this organ accumulated ten-fold greater concentrations of this compound than found in the flowers or leaves from immature plants. None of the other organs, the stems or roots, had any appreciable concentrations of **1**. Commercial seed sources of *D. inoxia*, *D. metel*, and *D. stramonium* were germinated and cultivated in the greenhouse. Leaves were collected and extracted. Again, LC-MS analyses were conducted to screen for the indicator *m/z* 655 ion. Only leaf extracts from *D. inoxia* contained **1**; it was not detected in extracts from leaves of *D. metel* or *D. stramonium*.

The estrogen receptor-positive (ER⁺) breast cancer cell line MCF-7¹⁹ was used throughout the extraction process in the bioassay-guided fractionation of the *Datura* extracts. The characteristic mass spectrum of the active HPLC fraction against MCF-7 was determined and this chemical signature was used to purify **1**. The specificity of **1** was investigated by bioassays against a number of normal (n=3) and cancer cell lines (n=21); these IC₅₀ values are presented in Table 2. Compound **1** exhibited sub-micromolar activity against several

cancer cell lines with breast cancer cell lines being consistently among the most sensitive. Compound **1** is unusual in that it has sub-micromolar cytotoxicity levels as a glucosylated form of a withanolide. All other withanolide glycosides have less cytotoxicity relative to their aglycone forms.^{15,20,21} To determine if the presence of the glucosyl group at C-27 on **1** influenced the biological activity, **2** was generated and used in bioassays. The IC₅₀ values for **2** against the T47D, MDA-MB468 and MCF-7 cell lines were 0.99 ± 0.09 , 0.75 ± 0.05 and 0.87 ± 0.22 , respectively. In each case, the most potent cytotoxic compound was **1**; compound **2** was slightly less active (Table 2). This is in direct contrast to the bioactivities of other withanolides; the published IC₅₀ values for withaferin A and its glycoside form against MCF-7 cells are 0.6 and 7.9 μ M, respectively.²⁰ In the case of withaferin A, unlike compound **1**, the presence of a glucose group on the withanolide reduces the bioactivity ten-fold.

Experimental Section

General Experimental Procedures

UV/vis spectra were recorded on a Beckman-Coulter DU-640 UV/vis spectrophotometer. IR spectra were recorded on a Biorad FTS-6000 spectrometer from KBr pellets. NMR spectra were collected in *d*₆-DMSO at 27° C with a Bruker Avance 500 using a 5 mm BBO probe. The data were processed with Bruker Topspin 1.3 and the chemical shift predictions made using ACD/ChemSketch (Toronto, Ontario, Canada) version 12.01. Chemical shifts are reported as parts per million from TMS based on the lock solvent. NMR spectra were also collected at 25 °C in CDCl₃ on a Varian Unity Inova 500 MHz NMR spectrometer equipped with a Varian triple resonance/pulse field gradient probe. HRMS was performed on an Applied Biosystems/MDS Sciex Q-Star Elite Q-TOF mass spectrometer with a Turboionspray electrospray source, with an Agilent 1100 series HPLC system (G1379A degasser, G1357A binary capillary pump, G1389A autosampler, G1315B photodiode array detector, and a G1316A column oven) all running under Applied Biosystems Analyst 2.0 (build 1446) LC-MS software. The MS was calibrated at least once daily with a standard calibration mixture recommended by Applied Biosystems and the signal detection was optimized as needed. The data was acquired in the positive TOF MS mode. The MS parameters were as follows: accumulation time - 1 sec, mass range 200 to 1000 daltons, source gas 1 - 50 units, source gas 2 - 35 units, curtain gas - 25 units, ion spray voltage 4500, source heater - 400 °C, declustering potential -80, focusing potential - 265, declustering potential 2 - 15, ion release delay - 6, ion release width - 5. For HRMS determination the samples were mixed with a standard calibrant and infused directly into the MS. For LC-MS analysis, the column used was an Inertsil ODS-3 reverse phase C₁₈ column (3 μ m, 150 \times 3 mm, with a Metaguard column, from Varian). The initial conditions were 20% methanol and 0.2% acetic acid in water, at a flow rate of 0.25 mL per min. The effluent was monitored at 280 nm using the PDA detector. After a delay of two min, the column was developed to 100% methanol with a linear gradient over 60 min.

Plant Material

Datura innoxia Mill. (*Datura wrightii* Regel) and *Datura stramonium* L. samples were collected on the New Mexico State University (NMSU) campus in Las Cruces, Doña Ana county in southern New Mexico; *D. innoxia*, *D. metel* L., and *D. stramonium* plants were also grown from seed (Horizon Herbs, Williams OR) in a greenhouse on the NMSU campus. A voucher specimen of the *D. innoxia* collected from the NMSU unmanaged campus area October 2004 was submitted to the Range Science Herbarium at NMSU [Holguin 1 (NMCR)]. Plant identification for field-collected plants was confirmed by K. Allred, range plant taxonomist at NMSU. Recollections of *D. innoxia* from this same population on the NMSU campus have been carried out annually in the fall months of 2006, 2008, and 2009.

Extraction and Isolation

One kg of dried, pulverized *D. innoxia* leaves were extracted in 10 g aliquots in an ASE 350 liquid extraction apparatus. A 5 mL layer of sand was placed in each 35 mL cell, followed by a mixture of the crushed leaves and sufficient sand to fill the cell (ca. 15 g). The samples were extracted three times with hexane (80° C, 8 min static extraction, 50% rinse volume, 60 sec purge), followed by three extractions with chloroform (same conditions, but 100 second purge). Finally, the sample was extracted four times with methanol (same conditions as for chloroform extractions). The methanol extracts contained the active principle and were diluted with an equal volume of water, then centrifuged to remove the insoluble precipitate. The supernatant was extracted with half a volume of hexane and pooled. The methanol phase was loaded onto a 20 mL (5 g) LC-18 column (Supelco) in 250 mL aliquots. After washing the column extensively with 30% (v/v) methanol, the concentrated sample was eluted with 100% methanol. Four volumes of anhydrous ethyl ether were slowly added to the extract (with continuous stirring) at 0 °C. The sample was centrifuged for 15 min (10,000 × g, 4 °C) to remove the insoluble precipitate. The supernatant was collected, and the ether was removed under a stream of nitrogen at ~50 °C. Semi-preparative HPLC was then performed using a Waters HPLC system: 10 × 100 mm Waters Atlantis Prep C₁₈ column (5 μm), using a 6 mL/min linear gradient of 20% to 60% (v/v) acetonitrile in 0.1% trifluoroacetic acid. Following 1 min of 20% acetonitrile, the gradient slope was 5% per min. The column was pre-run at 54 °C with 100% acetonitrile and equilibrated with 20% acetonitrile prior to each injection. Absorbance was monitored at 271 nm using a Waters 960 photodiode array with the major peak collected at approximately 7.35 min. This material was diluted with an equal part of water and concentrated on an LC-18 column as before. Approximately 50 mg of purified material was obtained.

For structural analysis, an additional purification using a Shimadzu (Columbia, MD) preparative HPLC system was used with dual 8A pumps, SIL 10vp autoinjector, SPD M10Avp photodiode array detector, SCL 10Avp system controller all operating under the Shimadzu Class VP operating system. Sample aliquots (1 mL) in methanol were injected on a Phenomenex (Torrance, CA) Luna C18(2) semi-preparative reverse-phase column (5 μm, 100 Å, 250 × 25 mm). The column was pre-equilibrated with 1% acetic acid, 20% methanol, and 79% water at a flow rate of 10 mL per min. and the effluent was monitored at 280 nm. The column was developed to 100% methanol over 45 min. The procedure was repeated to obtain sufficient purified material. Pooled material was allowed to evaporate to remove organic solvent, and then freeze-dried to recover **1**.

Dinoxin B (1)

Light brown amorphous solid; $[\alpha]_D^{25} -36.5$ (c 5, MeOH); UV (MeOH) λ_{\max} (log ϵ), 230, 314 (3.60) nm; IR (KBr, disk) λ_{\max} : 3409, 2910, 1683, 1664(sh), 1395, 1077, 1050(sh), 798; HREIMS positive ion m/z 655.3146 $[M+Na]^+$ (calcd for C₃₄H₄₈O₁₁Na, 655.3088); with major fragments m/z 471.2830 $[M\text{-glucose}+H]^+$ (calcd for C₂₈H₃₉O₆ 471.2741) and 453.2686 $[M\text{-glucose-water}+H]^+$ (calcd for C₂₈H₃₇O₅ 453.2635). For ¹H NMR (DMSO-*d*₆, 500 MHz) and ¹³C NMR (DMSO-*d*₆, 125 MHz) spectroscopic data, see Table 1.

Hydrolysis of Dinoxin B (1)

Dinoxin B (**1**, 10 mg) was dissolved in 1 mL of 10 % aqueous HCl:dioxane (1:1). The solution was heated at 85–90 °C for 5 h in an oil bath. The mixture was neutralized (NaHCO₃) and extracted with ethyl acetate (2 × 1 mL), dried (Na₂SO₄), and evaporated to afford a brown residue. The residue was purified using flash chromatography 5% MeOH-CH₂Cl₂ to afford the aglycone (**2**) as a colorless oil (3 mg, 40 % yield). $[\alpha]_D^{25} -15.2$ (c 1, MeOH), HRMS positive ion m/z 470.2884 $[M+H]^+$ (calcd for C₂₈H₃₈O₆ 470.2741). For ¹H NMR and ¹³C NMR (CDCl₃, 500 MHz) spectroscopic data, see Table 1.

Mammalian Cancer Cell Assays

Cell viability evaluation was carried out using an ATP-sensitive CellTiterGlo luminescent assays. Cells, typically 5,000–15,000 per well, were plated in 96-well microtiter plates. Cells were allowed to adhere using a standard growth culture medium and conditions as recommended by the ATCC. After 24 h, the medium was replaced and test compounds were added with a final DMSO concentration of <0.1%. Cells were grown in the presence of test compounds for 48 h at which time medium was replaced with drug-free medium. Cells were allowed to recover for 24 h. The CellTiter Glo reagent was added directly to the medium and luminescence was measured using a Packard TopCount microtiter plate luminometer. Cytotoxicity, relative to vehicle treated controls, as determined using this method, was highly consistent with the ³H-thymidine incorporation assay.²²

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported in part by the New Mexico Agricultural Experiment Station, and NIH grants NCI U56 CA96286 and U54 CA132383. The authors would like to thank Sandra M. Duval and Ray K. Holloway for their technical support, Dr. Michael Bowman for his expert advice and guidance in the structure elucidation of dinoxin B, Dr. Sheryl Gordon for performing the IR analysis, Dr. Michele Scian and Dr. William Atkins at the Department of Medicinal Chemistry, University of Washington, Seattle for use of their NMR facility and assistance with the aglycone structure elucidation.

References and Notes

1. Preissel, H.; Preissel, U. *Brugmansia* and *Datura* Angel's Trumpets and Thorn Apples. Buffalo: Firefly Books Ltd.; 2002. p. 106-136.
2. Evans, WC. Solanaceae Biology and Systematics. D'Arcy, WG., editor. New York: Columbia University Press; 1986. p. 179-186.
3. Abraham A, Kirson I, Lavie D, Glotter E. *Phytochemistry* 1975;14:189–194.
4. Manickam M, Srivastava A, Ray A. *Phytochemistry* 1998;47:1427–1429.
5. Veleiro AS, Cirigliano A, Oberti JC, Burton G. *J. Nat. Prod* 1999;62:1010–1012. [PubMed: 10425128]
6. Siddiqui BS, Shamsul A, Sabira B. *Aust. J. Chem* 1999;52:905–907.
7. Siddiqui S, Arfeen S, Begum S, Sattar F. *Nat. Prod. Res* 2005;19:619–623. [PubMed: 16010830]
8. Gupta M, Bagchi A, Ray AB. *J. Nat. Prod* 1991;54:599–602.
9. Pan Y, Wang X, Hu X. *J. Nat. Prod* 2007;70:1127–1132. [PubMed: 17583953]
10. Kagale S, Marimuthu T, Thayumanavan B, Nandakumar R, Samiyappan R. *Physiol. Mol. Plant Pathol* 2004;65:91–100.
11. Siddiqui S, Naheed S, Ahmad S, Haider I. *Phytochemistry* 1987;9:2641–2643.
12. Stan SD, Hahm E-R, Warin R, Singh SV. *Cancer Res* 2008;68:7661–7669. [PubMed: 18794155]
13. Chen W-Y, Chang F-R, Huang Z-Y, Chen Y-H, Wu Y-C, Wu C-C. *J. Biol. Chem* 2008;283:17184–17193. [PubMed: 18442981]
14. Evans WC, Grout RJ, Mensah MLK. *Phytochemistry* 1984;23:1717–1720.
15. Ma L, Xie C-M, Li J, Lou F-C, Hu L-H. *Chem. Biodivers* 2006;3:180–186. [PubMed: 17193256]
16. Minguzzi S, Barota LES, Shin YG. *Phytochemistry* 2002;59:635–641. [PubMed: 11867095]
17. Sinha SC, Kundu S, Maurya R, Ray AB. *Tetrahedron* 1989;45:2165–2176.
18. Ghosal S, Kaur R, Srivastava RS. *Indian J. Nat. Prod* 1988;4:12–13.
19. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe J-P, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo W-L, Stilwell JL, Pinkel D, Albertson

- DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. *Cancer Cell* 2006;10:515–527. [PubMed: 17157791]
20. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG. *Life Sci* 2003;74:125–132. [PubMed: 14575818]
21. Hseih P-W, Huang Z-Y, Chen J-H, Chang F-R, Wi C-C, Yang MY, Yen M-H, Chen S-L, Lubken T, Hung W-C, Wu Y-C. *J. Nat. Prod* 2007;70:747–753. [PubMed: 17417907]
22. Lamb JR, Goehle S, Ludlow C, Simon JA. *Biotechnology* 2001;30:1118–1120.

Table 1

¹H and ¹³C NMR Spectroscopic Data for Dinoxin B (1) and its Aglycone (2).

position	Compound 1			Compound 2		
	δ _C mult.	δ _H (J in Hz)	HMBC ^a	δ _C mult.	δ _H (J in Hz)	HMBC ^a
1	203.9, C			210.51		
2	127.3, CH	5.81, dd (9.9, 2.7)		126.86	5.67, m	1, 4
3	147.4, CH	6.94, ddd (9.9, 4.9, 2.3)	4, 10	130.06	6.07, d (8.4)	4
4	33.2, CH ₂	3.30, 2.89, d (21.4, 4.9)	1, 4, 5	39.61	3.31, 2.77, d (20) dd (20,5)	10, 1, 2, 3, 5
5	136.4, C			140.86		
6	124.6, CH	5.59, d (5.9)	4, 7, 8, 10	121.61	5.67, m	7, 10
7	30.5, CH ₂	1.93, 1.49, dt (17.6, 4.9), m	5, 6, 8, 9	30.58	2.21, 1.6, m, m	5, 8, 9
8	32.3, CH	1.29, m	1, 9, 10, 13	30.74	1.51, m	b
9	42.0, CH	1.58, m	1, 7, 8, 10, 11, 19	39.79	1.91, m	b
10	50.2, C			51.47		
11	33.4, CH ₂	2.26, 1.39, dt (13.0, 4.1), q (12.1)	8, 9, 10, 12, 13	33.91	2.05, 1.38, m, m	8, 9, 13, 12
12	77.8, CH	3.42, dd (11.5, 4.1)	11, 13, 18	76.10	3.69, m	18, 13
13	47.7, C			48.63		
14	54.2, CH	1.04, dd (11.1, 7.0)	8, 12, 13, 15, 18	54.20	1.22, m	b
15	24.0, CH ₂	1.59, 1.19, m, m	8, 16	23.51	1.76, 1.38, m, m	b
16	26.9, CH ₂	1.75, 1.50, m, m	13	26.65	1.85, 1.52, m, m	b
17	48.3, CH	1.73, m	13, 16, 20, 22	39.85	1.95, m	b
18	7.9, CH ₃	0.71, s	12, 13, 14	7.68	0.75, s	12, 13, 14
19	18.9, CH ₃	1.16, s	1, 5, 9, 10	20.23	1.35, s	1, 5, 10, 9
20	45.3, CH	1.84, m	17, 22	49.23	1.94, m	b
21	59.6, CH ₂	3.74, 3.67, dd (11.5, 3.7), dd (11.4, 1.4)	17, 22	61.63	3.75, m	20, 17
22	77.7, CH	4.44, dt (12.8, 3.8)	20, 21, 24	75.77	4.61, m	17, 20
23	33.0, CH ₂	2.76, 2.32, dd (18.3, 13.0), dd (18.3, 2.9)	22, 24, 25, 28	30.56	1.96	b
24	158.7, C			139.40		
25	122.4, C			129.20		
26	165.6, C			165.39		

Compound 1				Compound 2			
position	δ_C mult.	δ_H (J in Hz)	HMBC ^a	δ_C mult.	δ_H (J in Hz)	HMBC ^a	
27	62.5, CH ₂	4.51, 4.24, d (10.9), d (10.9)	24, 25, 26, 1'	62.27	4.74, m	26	
28	20.7, CH ₃	2.04, s	23, 24, 25, 26, 27	25.88	1.45, s	23, 24, 25, 26	
1'	103.2, CH	4.17, d (7.9)	27, 3'				
2'	73.8, CH	2.93, t (8.3)	1', 3'				
3'	77.2, CH	3.13, t (8.6)					
4'	70.6, CH	3.04, m	5'				
5'	77.4, CH	3.08, m	6'				
6'	61.6, CH ₂	3.67, 3.44, dd (11.5, 1.7), dd (11.9, 5.6)	4', 5'				

^a HMBC correlations, optimized for 10 Hz, are from proton(s) stated to the indicated carbon.

^b Correlations not assigned unambiguously due to multiplicity of the peaks in this region.

Table 2Cytotoxicity in Human Cancer Cell Lines of Dinoxin B (**1**)^a

type	cell line	IC ₅₀ (μM)	type	cell line	IC ₅₀ (μM)
breast	MDA-MB453	3.0 ± 0.05	liver	HEPG2	1.5 ± 0.04
	MDA-MB231	1.0 ± 0.07		HUH7	1.5 ± 0.02
	MCF7	0.61 ± 0.05	normal	HEP3B	0.67 ± 0.29
	MDA-MB468	0.58 ± 0.07		IEC6	3.3 ± 0.05
	HS578T	0.44 ± 0.38		NHF177	1.23 ± 0.06
colon	T47D	0.22 ± 0.06	melanoma	HUVEC	0.74 ± 0.09
	Colo205	2.2 ± 0.12		SK-MEL28	2.3 ± 0.05
	HCT116	1.0 ± 0.07		SK-MEL5	1.4 ± 0.03
	SW48	0.58 ± 0.08		UACC62	0.50 ± 0.03
	RKO	0.36 ± 0.02		SK-MEL2	0.36 ± 0.05
lung	A549	3.4 ± 0.02	ovarian	OVCAR3	3.2 ± 0.06
	A427	0.87 ± 0.03			

^aNormal and cancer cell lines, organized by organ source were treated with varying doses of **1** to determine the IC₅₀ using the CellTiter-Glo luminescent cell viability assay.